1.7M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 915,000 | 915,000 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| John Edward Robinson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Cole Pinnow | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 7.60 per share. | 14 Jan 2025 | 43,750 | 45,848 (0%) | 0% | 7.6 | 332,413 | Common Stock |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 2,785 | 2,785 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 2,034 | 2,034 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 2,462 | 2,462 | - | - | Stock Option (Right to Buy) | |
| Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Todd E. Shegog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Peter Harwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Christopher W. Cain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Cole Pinnow | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 3,213 | 3,213 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| John Robinson Edward | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Green L. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 255,000 | 255,000 | - | - | Stock Option (Right to Buy) | |
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,100,000 | 1,100,000 | - | - | Stock Option (Right to Buy) | |
| Jean Karen Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,298 | 3,298 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,051 | 3,051 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,743 | 1,743 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,884 | 1,884 | - | - | Stock Option (Right to Buy) | |
| Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Todd E. Shegog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Peter Harwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Christopher W. Cain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 1,900 | 1,900 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 2,053 | 2,053 | - | - | Stock Option (Right to Buy) | |
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| John Edward Robinson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 160,000 | 160,000 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,792 | 1,792 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,862 | 1,862 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 1,419 | 1,419 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 1,474 | 1,474 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 2,194 | 2,194 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 2,279 | 2,279 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 7.40 per share. | 30 Jun 2022 | 622 | 622 (0%) | 0% | 7.4 | 4,600 | Common Stock |
| Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Todd E. Shegog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Peter Harwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Christopher W. Cain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,650 | 2,650 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,753 | 2,753 | - | - | Stock Option (Right to Buy) | |
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 690,000 | 690,000 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 202,250 | 202,250 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| John Edward Robinson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,256 | 2,256 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,329 | 2,329 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,463 | 2,463 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,385 | 2,385 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,225 | 2,225 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,513 | 2,513 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 26 Apr 2021 | 17,813 | 3,841 (0%) | 0% | 8.9 | 157,823 | Common Stock |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,068 | 2,068 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,121 | 2,121 | - | - | Stock Option (Right to Buy) | |
| Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Todd E. Shegog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Peter Harwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Christopher W. Cain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 524 | 21,654 (0%) | 0% | 0 | Common Stock | |
| Todd E. Shegog | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 315,200 | 315,200 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 270,746 | 270,746 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 111,300 | 111,300 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 126,500 | 126,500 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,641 | 1,641 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 1,575 | 1,575 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 1,748 | 1,748 (0%) | 0% | 0 | Common Stock | |
| Andrews R. Robbins | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2020 | 7,442,421 | 7,442,421 | - | - | Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2020 | 695,700 | 695,700 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 9,247 | 9,247 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 8,878 | 8,878 | - | - | Stock Option (Right to Buy) | |
| Chris Cain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2020 | 28,661 | 28,661 | - | - | Director Stock Option (Right to Buy) | |
| Peter Harwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2020 | 28,661 | 28,661 | - | - | Director Stock Option (Right to Buy) | |
| John L. Green | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.20 per share. | 06 Jul 2020 | 31,873 | 77,586 (0%) | 0% | 2.2 | 70,121 | Common Stock |
| John L. Green | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2020 | 109,459 | 0 | - | - | Restricted Stock Units | |
| John L. Green | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2020 | 109,459 | 109,459 (0%) | 0% | - | Common Stock | |
| Joern Aldag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 40,090 | 40,090 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 35,280 | 35,280 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 38,487 | 38,487 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 61,338 | 61,338 | - | - | Stock Option (Right to Buy) | |
| Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2020 | 56,690 | 56,690 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2020 | 49,887 | 49,887 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2020 | 54,422 | 54,422 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2020 | 86,735 | 86,735 | - | - | Stock Option (Right to Buy) | |
| John L. Green | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 64,400 | 64,400 | - | - | Stock Option | |
| Seth Ettenberg | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 153,600 | 153,600 | - | - | Stock Option | |
| Geoffrey Hodge | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 112,400 | 112,400 | - | - | Stock Option | |
| Matthew Osborne | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 160,400 | 160,400 | - | - | Stock Option | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2020 | 133,200 | 133,200 | - | - | Stock Option | |
| Joern Aldag | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 29,790 | 29,790 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 24,274 | 24,274 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 26,480 | 26,480 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 39,996 | 39,996 | - | - | Stock Option (Right to Buy) | |
| John L. Green | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2019 | 109,459 | 109,459 | - | - | Restricted Stock Units | |
| Seth Ettenberg | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2019 | 280,000 | 280,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 15,352 | 15,352 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 12,509 | 12,509 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 13,646 | 13,646 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 20,611 | 20,611 | - | - | Stock Option (Right to Buy) | |
| Arlene M. Morris | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2019 | 28,661 | 28,661 | - | - | Stock Option (Right to Buy) | |
| Matthew E. Ros | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2019 | 28,661 | 28,661 | - | - | Stock Option (Right to Buy) | |
| Jessica Sachs | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2019 | 123,800 | 123,800 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2019 | 7,608 | 7,608 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2019 | 6,199 | 6,199 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2019 | 10,285 | 10,285 | - | - | Stock Option (Right to Buy) | |
| Matthew Osborne | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2019 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2019 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2019 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2019 | 14,331 | 14,331 | - | - | Stock Option (Right to Buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2019 | 7,131 | 7,131 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2019 | 7,881 | 7,881 | - | - | Stock Option (Right to Buy) | |
| John L. Green | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2019 | 16,814 | 16,814 | - | - | Stock Option (Right to Buy) | |
| John L. Green | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2019 | 21,017 | 21,017 | - | - | Stock Option (Right to Buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 4,369 | 4,369 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 4,966 | 4,966 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 4,829 | 4,829 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 4,047 | 4,047 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 6,714 | 6,714 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2019 | 11,485 | 329,145 | - | - | Stock Option (Right to Buy) | |
| Charles Wilson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 174,400 | 174,400 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 69,700 | 69,700 | - | - | Stock Option (Right to Buy) | |
| Michael Vasconcelles | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 61,900 | 61,900 | - | - | Stock Option (Right to Buy) | |
| Geoffrey Hodge | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.25 per share. | 25 Feb 2019 | 11,485 | 0 (0%) | 0% | 4.3 | 48,853 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2019 | 11,485 | 340,630 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 25 Feb 2019 | 11,485 | 11,485 (0%) | 0% | 0.2 | 2,067 | Common Stock |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 4,397 | 4,397 | - | - | Stock Option (Right to Buy) | |
| Joern Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 4,999 | 4,999 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 4,860 | 4,860 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 4,073 | 4,073 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 6,757 | 6,757 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 26 Dec 2018 | 11,485 | 11,485 (0%) | 0% | 0.2 | 2,067 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2018 | 11,485 | 352,115 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 26 Dec 2018 | 11,485 | 0 (0%) | 0% | 4.0 | 46,487 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2018 | 11,485 | 363,600 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 26 Nov 2018 | 11,485 | 0 (0%) | 0% | 7.0 | 80,444 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 26 Nov 2018 | 11,485 | 11,485 (0%) | 0% | 0.2 | 2,067 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 25 Oct 2018 | 11,485 | 11,485 (0%) | 0% | 0.2 | 2,067 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 25 Oct 2018 | 11,485 | 0 (0%) | 0% | 8.5 | 97,201 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2018 | 11,485 | 375,085 | - | - | Stock Option (Right to Buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 1,910 | 1,910 | - | - | Stock Option (Right to Buy) | |
| Jorn Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 2,171 | 2,171 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 2,111 | 2,111 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 1,769 | 1,769 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 2,935 | 2,935 | - | - | Stock Option (Right to Buy) | |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 25 Sep 2018 | 11,485 | 11,485 (0%) | 0% | 0.2 | 2,067 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.47 per share. | 25 Sep 2018 | 11,485 | 0 (0%) | 0% | 12.5 | 143,181 | Common Stock |
| Seth Ettenberg | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2018 | 11,485 | 386,570 | - | - | Stock Option (Right to Buy) | |
| Robert J. Perez | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 1,361 | 1,361 | - | - | Stock Option (Right to Buy) | |
| Jorn Aldag | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 1,547 | 1,547 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 1,504 | 1,504 | - | - | Stock Option (Right to Buy) | |
| Karen Jean Ferrante | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 1,261 | 1,261 | - | - | Stock Option (Right to Buy) | |
| Bruce Booth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2018 | 2,092 | 2,092 | - | - | Stock Option (Right to Buy) | |
| Liam Ratcliffe | None | 03 Apr 2018 | 977,836 | 0 | - | - | Series B Preferred Stock | ||
| Liam Ratcliffe | None | 03 Apr 2018 | 622,772 | 622,772 (2%) | 2% | 0 | Common Stock | ||
| Liam Ratcliffe | None | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 03 Apr 2018 | 275,000 | 897,772 (3%) | 0% | 12 | 3,300,000 | Common Stock |
| Liam Ratcliffe | None | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 03 Apr 2018 | 275,000 | 897,773 (3%) | 0% | 12 | 3,300,000 | Common Stock |
| Liam Ratcliffe | None | 03 Apr 2018 | 977,835 | 0 | - | - | Series B Preferred Stock | ||
| Liam Ratcliffe | None | 03 Apr 2018 | 622,773 | 622,773 (2%) | 2% | 0 | Common Stock | ||
| Bruce Booth | None | 03 Apr 2018 | 83,037 | 0 | - | - | Series B Preferred Stock | ||
| Bruce Booth | None | 03 Apr 2018 | 3,184,446 | 0 | - | - | Series A Preferred Stock | ||
| Bruce Booth | None | 03 Apr 2018 | 3,184,446 | 3,184,446 (10%) | 10% | 0 | Common Stock | ||
| Bruce Booth | None | 03 Apr 2018 | 83,037 | 3,267,483 (11%) | 0% | 0 | Common Stock | ||
| Bruce Booth | None | Purchase of securities on an exchange or from another person at price $ 12.00 per share. | 03 Apr 2018 | 94,052 | 3,361,535 (11%) | 0% | 12 | 1,128,624 | Common Stock |